Johnson & Johnson CEO Joaquin Duato’s warning earlier this month that the outlook for 2023 remains uncertain is tempering investor expectations ahead of the company’s earnings reports on Tuesday. ...
Tag: Healthcare/Life Sciences
Salesforce, Abbott, Spotify, and More Stock Market Movers
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...
Tesla, AT&T, Visa, Chevron, Microsoft, and More Stocks to Watch This Week
We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. We’ve detected you are on Internet Explorer. For the best Barrons.com e...
Tesla, AT&T, Visa, Chevron, Microsoft, and More Stocks for Investors to Watch This Week
We’ve detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. We’ve detected you are on Internet Explorer. For the best Barrons.com e...
GE set to report final pre-breakup earnings
General Electric Co. is scheduled to report next week its final quarterly results before the start of its breakup, with the industrial conglomerate expected to report its highest profit since before t...
CureVac Stock Just Got Upgraded. It’s Now a Competitor in mRNA Vaccines.
CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVA...
Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.
Nearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime soon. With real...
Fed’s Powell won’t stop rate hikes until he ‘terrifies’ the wealthiest of investors, says this CIO
Investors are waking up to a whiff of positivity where stocks are concerned for Monday, after last week’s first gain in five that was prompted by weak wage growth Alongside a bleak Institute for Suppl...
European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas
European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN, +1.42% AZN, -1.26% said it’s pay...
It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.
My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...
AbbVie cuts earnings forecast due to milestone payments
AbbVie Inc. executives lowered their outlook for the quarter and year in a filing with the Securities and Exchange Commission late Friday, which cited research and development expenses and milestone p...
Generac stock leads S&P 500 gainers after Janney says buy, citing ‘free option’ on clean energy
Shares of Generac Holdings Inc. surged Wednesday, after Janney analyst Sean Milligan said the sharp selloff this year has provided investors an opportunity to buy into an established brand with a domi...
Stocks Limp Toward 2023 as the Data Show Few Signs of a Clear Direction
Stocks limped on the low volumes of the pre-Christmas week, battered by conflicting data and leaving investors with a muddled outlook going into 2023. It’s a dynamic in which good news and bad news te...
Stocks remain overpriced, even vs. the dot-com bubble. But you can still find good picks in these 2 sectors.
After stocks surged to their best gains in three weeks following strong consumer sentiment data, Thursday is looking less spirited with stocks in the red as we close in on the long Christmas weekend. ...
Earn extra money with a side gig—here are 6 good ones for retirees
If inflation and the gyrating stock market has you fretting over your financial security in retirement, you’re not alone. Fully 71% of boomers recently surveyed by Bankrate said they are behind on ret...
GE HealthCare Stock Is Trading. We Were Wrong.
The GE HealthCare spinoff General Electric is going to be a big event for the company, and investors, in the new year. Shares begin trading, officially, on Jan. 4. Some are trading now too and the pri...
BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline
Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines tha...
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis
Clovis Oncology Inc., maker of the ovarian and prostate cancer drug Rubraca, filed for bankruptcy over the weekend with a proposed deal in hand to sell its rights to a cancer therapy under development...
What investors need to know about Pfizer’s latest downgrade
Pfizer’s PFE, -0.92% early-stage pipeline, though promising, is still too premature to make up for the looming loss of billions of dollars from the company’s COVID-19 franchise, which includes the vac...